

ABSTRACT OF THE DISCLOSURE

The present invention provides a gene delivery system
5 that combines transductional targeting via binding to angiotensin
converting enzyme (ACE) expressed on pulmonary endothelial cells
with transcriptional targeting using the vascular endothelial growth
factor type 1 receptor (flt-1) promoter. Compared to either approach
used alone, this combined targeting approach resulted in a dramatic
10 improvement in the target : non-target transgene expression ratio *in*
vivo, thereby improving the prospects for pulmonary vascular gene
therapy and establishing a fundamental principal for the use of
targeting strategies generally.